공시 • Mar 12
Psyched Wellness Ltd. announced that it expects to receive CAD 1.719307 million in funding from Gotham Green Partners, LLC and affiliates and or co-investors of Gotham Green Psyched Wellness Ltd. announced that it has entered into a non-binding term sheet with returning investors Gotham Green Fund I, L.P. and Gotham Green Fund I (Q), L.P. pursuant to which the Company shall complete a non-brokered private placement and will issue 170,228,410 common shares and common share purchase warrants for aggregate gross proceeds of up to CAD 1,719,306.941 on March 11, 2026. The Offering will be led by Gotham Green, and it may include affiliates and/or co-investors of Gotham Green. The company will raise proceeds in two tranches of up to CAD 859,653.47 each, subject to closing conditions. The Offering will consist of issuances of Common Shares at a price of CAD 0.0101 per Common Share and Warrants at a price of CAD 0.005 per Warrant. Each Warrant will entitle the holder thereof to acquire one additional Common Share at a price of CAD 0.0051 per Additional Share at any time on or before the Warrant expiry date, set sixty (60) months following the applicable closing date. The Company has obtained approval from the Canadian Securities Exchange (the "CSE") to issue the Common Shares and Warrants at a price lower than CAD 0.05 as the Offering Price is above the volume weighted average trading price of the Common Shares on the CSE for the 20 trading day period ending March 10, 2026. The Offering will be offered for purchase and sale to investors in the United States on a private placement basis. The initial tranche is scheduled to close on or about March 18, 2026 (the "Tranche 1 Closing Date") for aggregate gross proceeds of CAD 859,653.47 (the "Initial Tranche"). Subject to the policies of the CSE, closing of the second and final tranche could be for up to CAD 859,653.47 ("Tranche 2"). The Investor Group has no obligation to fund Tranche 2, and may elect to complete Tranche 2 in whole or in part or not at all in the Investor Group's sole discretion. Additionally, the closing of Tranche 2 shall be subject to satisfactory completion of due diligence in the Investor Group's sole discretion. All securities issued under the Offering will be subject to a four month and one day hold period from the applicable closing date and applicable legends as required pursuant to the U.S. Securities Act. Closing of the Offering is subject to customary closing conditions, including the approval of the CSE. 공시 • Nov 27
Psyched Wellness Ltd. Launches Calmer Psyched Wellness Ltd. announced the launch of Calmer, a new product offering that delivers twice the potency of its product, Calm. The Company has also enhanced the flavour profile of Calm in both the 30 ml and 60 ml formats, reducing the mushroom taste while maintaining potency and consumer experience. The launch coincides with Psyched's Black Friday promotion, offering customers a 40% discount site-wide (excluding merch) through December 1, 2025. 공시 • Apr 10
AME Wellness Inc. Working with its Advisors, Zerkalo LLC Completes an Initial Pilot Run of New Dietary Supplement in Form of 4 oz Shot Psyched Wellness Ltd. announced that its US subsidiary, AME Wellness Inc., working with its advisors, Zerkalo LLC, have completed an initial pilot run of new dietary supplement in form of a 4 oz shot. The purpose of this pilot run is to beta test the shot with a select target group of consumers and gather feedback on the taste, the effect, and marketing data relating to the product. As part of this process, the Company will stress test its website, 3pl and shipping process to ensure that its fulfilment capabilities are in place in advance of the product launch. 공시 • Mar 04
Psyched Wellness Ltd., Annual General Meeting, May 15, 2025 Psyched Wellness Ltd., Annual General Meeting, May 15, 2025. 공시 • Nov 27
Psyched Wellness Ltd. Announces Resignation of Harrison Aaron as Director Psyched Wellness Ltd. announced that Harrison Aaron, a nominee of Gotham Green Partners, LLC ("Gotham Green"), has resigned as a director of the Company effective November 22, 2024. New Risk • Jul 31
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €7.69m (US$8.33m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 21% per year over the past 5 years. Shareholders have been substantially diluted in the past year (98% increase in shares outstanding). Revenue is less than US$1m (CA$469k revenue, or US$339k). Market cap is less than US$10m (€7.69m market cap, or US$8.33m). Reported Earnings • Jul 30
Second quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 2Q 2023) Second quarter 2024 results: CA$0.005 loss per share. Net loss: CA$1.30m (loss widened 65% from 2Q 2023). Reported Earnings • Apr 30
First quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.007 loss in 1Q 2023) First quarter 2024 results: CA$0.003 loss per share (improved from CA$0.007 loss in 1Q 2023). Net loss: CA$689.4k (loss narrowed 32% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings. Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Janeen Stodulski was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Mar 31
Full year 2023 earnings released: CA$0.021 loss per share (vs CA$0.032 loss in FY 2022) Full year 2023 results: CA$0.021 loss per share (improved from CA$0.032 loss in FY 2022). Net loss: CA$3.43m (loss narrowed 20% from FY 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings. New Risk • Sep 06
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 72% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.4m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 39% per year over the past 5 years. Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Revenue is less than US$1m (CA$179k revenue, or US$131k). Minor Risk Market cap is less than US$100m (€13.5m market cap, or US$14.5m). New Risk • Aug 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$3.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.4m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 39% per year over the past 5 years. Revenue is less than US$1m (CA$179k revenue, or US$134k). Market cap is less than US$10m (€6.98m market cap, or US$7.66m). Minor Risk Shareholders have been diluted in the past year (7.5% increase in shares outstanding). Board Change • Jul 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Harrison Aaron was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. 공시 • Jun 22
Psyched Wellness Ltd. Announces Board Changes Psyched Wellness Ltd. announced that Amanda Galbraith has resigned as a director of the Company effective June 19, 2023. The Company also announced that Harrison Aaron has been appointed as director effective June 19, 2023. Harrison Aaron: Mr. Aaron is a Principal at Santa Monica based investment firm Gotham Green Partners, LLC ("Gotham Green") having joined the firm in early 2019. During his time at Gotham Green, in addition to helping lead the firm's broader investment efforts, he co-founded cannabis e-commerce retail and delivery business Amuse.com (currently serving Los Angeles, the Bay Area, and Sacramento), as well as co-founding Sandland Sleep (SandlandSleep.com), nationwide seller of highly-effective natural sleep aids, and is currently serving on the boards of both companies, as well as serving on the boards of VIOLA Brands and Engin Sciences. Prior to his time at Gotham Green, from 2013 to 2019, he covered the consumer sector as a senior analyst on the investment team at NYC-based JANA Partners, a multi-billion-dollar hedge fund investing in companies undergoing, or with the potential to undergo, value-unlocking changes. Mr. Aaron began his career on Goldman Sachs' Hedge Fund Strategies and Cross Asset Sales teams from 2009-2013, after graduating magna cum laude and Phi Beta Kappa from Colgate University, with high honors in Mathematical Economics. New Risk • Jun 15
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (47% average weekly change). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (CA$72k revenue, or US$54k). Market cap is less than US$10m (€7.53m market cap, or US$8.24m). Minor Risk Shareholders have been diluted in the past year (7.5% increase in shares outstanding). 공시 • May 20
Psyched Wellness Ltd., Annual General Meeting, Jul 11, 2023 Psyched Wellness Ltd., Annual General Meeting, Jul 11, 2023. 공시 • Feb 03
Psyched Wellness Ltd. Adds New Bottle Size for Their Amanita Muscaria Extract Calm Psyched Wellness Ltd. announced that they will be launching a new larger bottle size for their proprietary Amanita Muscaria Extract (AME-1) product Calm, on February 28th 2023. The new size will provide customers with double the servings per bottle, in a 60ml package. Calm is the first legal Amanita Muscaria extract available for sale in the USA. Board Change • Nov 16
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 2 experienced directors. No highly experienced directors. Independent Chairman Michael Nederhoff is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Apr 27
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 2 experienced directors. No highly experienced directors. Independent Chairman Michael Nederhoff is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Recent Insider Transactions • Apr 24
CEO & Director recently bought €84k worth of stock On the 19th of April, Jeffrey Stevens bought around 500k shares on-market at roughly €0.17 per share. This was the largest purchase by an insider in the last 3 months. Jeffrey has been a buyer over the last 12 months, purchasing a net total of €103k worth in shares. Is New 90 Day High Low • Feb 08
New 90-day high: €0.30 The company is up 340% from its price of €0.068 on 10 November 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is down 7.0% over the same period.